Reviva Pharmaceuticals Holdings, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-30
- Reviva Pharmaceuticals Holdings, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $3.80M, a 5.00% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $4.00M, a 60.66% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $10.17M, a 105.06% increase from fiscal 2022.
- Reviva Pharmaceuticals Holdings, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $4.96M, a 134.42% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $3.80M 10-K · filed 2026-03-30 | |
| 2024-12-31 | $4.00M 10-K · filed 2026-03-30 | $3.99M 10-K · filed 2025-04-03 |
| 2023-12-31 | $10.17M 10-K · filed 2025-04-03 | |
| 2022-12-31 | $4.96M 10-K · filed 2023-03-30 | |
| 2021-12-31 | $2.12M 10-K · filed 2022-03-15 | |
| 2020-12-31 | $616.86K 10-K/A · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |